Clinical Trials
2 trialsNCT02684617 2021-03-01
KEYNOTE-155
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT01515176 2018-03-15
Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed